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Abstract Type 1 diabetes mellitus is a chronic disease that
results from the autoimmune response against pancreatic
insulin producing β cells. Apart of several insulin regimens,
since the decade of 80s various immunomodulatory regi-
mens were tested aiming at blocking some steps of the
autoimmune process against β cell mass and at promoting
β cell preservation. In the last years, some independent
research groups tried to cure type 1 diabetes with an “im-
munologic reset” provided by autologous hematopoietic
stem cell transplantation in newly diagnosed patients, and
the majority of patients became free form insulin with
increasing levels of C-peptide along the time. In this review,
we discuss the biology of hematopoietic stem cells and the
possible advantages and disadvantages related to the high
dose immunosuppression followed by autologous hemato-
poietic stem cell transplantation.
Keywords Type 1 diabetes . Stem cell . Hematopoietic .
Cure . Diabetes . Immunosuppression . Autologous
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Introduction
Type 1 diabetes mellitus (T1DM) is a chronic disease that
results from the autoimmune response against pancreatic
insulin producing β cells. This autoimmune response begins
months or years before the first presentation of signs and
symptoms of hyperglycemia but at the time of clinical
diagnosis a small amount of β cell mass still remains [1].
In daily clinical practice, the main therapeutic option for
T1DM mellitus is multiple subcutaneous insulin injections,
which are shown to promote tighter glucose control and
reduce much of diabetic chronic complications, especially
microvascular complications [2].
Another important aspect related to long-term complica-
tions of type 1 diabetes is that in newly diagnosed patients
the larger the residual β cell function, the lower the micro-
vascular complications, and the lower the incidence of hy-
poglycemic events. In the face of this, β cell preservation is
a potential target in the management of type 1 diabetes and
its related complications [3].
Since the decade of 1980s, various immunomodulatory
regimens were tested, aiming at blocking some steps of the
autoimmune process against β cell mass and at promoting β
cell preservation, mainly in secondary prevention trials [4].
In this review, we summarize the benefits, risks, and
potential therapeutics of the most important studies involv-
ing β cell preservation by autologous nonmyeloablative
hematopoietic stem cell transplantation in newly-diagnosed
type 1 diabetes mellitus.
Overview about Stem Cells
Stem cells are identified in most tissues and contribute to
repair and restoration of cells that are destroyed following
damage or regular tissue turnover. They divide asymmetri-
cally, generating two distinct daughter cells: one copy of the
original stem cell and a second programmed to differentiate
[5]. Therefore, stem cells are mostly known by two func-
tional characteristics: self-renewal and multipotency. The
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first is observed when cellular divisions preserve stem cell
potential, important for the maintenance of the pool of stem
cells within a tissue. The latter is implicated in differentia-
tion into functionally distinct lineages. Embryonic stem
cells are on one end of the stemness spectrum and are
considered pluripotent, for their ability to differentiate into
tissues from any of the 3 germ layers [6]. Although resistant,
readily expandable, and easily manipulated in the laborato-
ry, safety issues, ethical concerns, and religious divergences
limit clinical studies using these cell types. Adult stem cells,
on the other end, are undifferentiated cells found in differ-
entiated tissues, which include cord blood, perinatal sources
(amnion, chorion and Wharton’s Jelly), and tissues from
fully formed organisms, from fetuses to adults [7–9].
Despite little tolerance to in vitro manipulation, low
proliferative potential, and restricted plasticity, these cells
have been extensively investigated in regenerative research.
Exceptions to these are mesenchymal stem cells, which are a
subset of adult stem cells that have a more immature behav-
ior, with better in vitro proliferation rates, higher differenti-
ation potential, and immunomodulatory effects [9].
Bone marrow is the most used stem cell source for
clinical research and practice. Although other tissues, such
as the adipose tissue [10], umbilical cord blood [11], and
umbilical cord tissue [12] may be considered better sources
of stem cells, bone marrow is still preferred in the clinical
setting due to its ease of access, abundance and previous
knowledge concerning safety, derived from conventional
bone marrow transplantation.
Autoimmunity in Type 1 Diabetes
Type 1 diabetes results from a cell-mediated autoimmune attack
against pancreaticβ cells. Since more than 70 % of β cell mass
has been destroyed at the time of clinical diagnosis, the auto-
immune process is markedly advanced when hyperglycemia
appears [1]. The rate of β cell destruction is rapid in children
associated with much less β cell mass at the time of diagnosis;
in contrast, in adults the rate of autodestruction is slower with
larger β cell mass at diagnosis [13]. In the later stage of the
natural history of the disease, there is a reduction of β cell mass
as manifested by low or undetected C-peptide plasma levels.
Autoimmune destruction of β cells is the result of the
wide interplay between genetic susceptibility and environ-
mental factors that are both still poorly defined [14]. The
concordance for type 1 diabetes is only 50 % for monozy-
gotic twins and the risk of first degree relative is approxi-
mately 5 % [9]. The most important, but not the only genetic
determinant to T1DM is the major histocompatibility com-
plex. More than 90 % of patients who develop type 1
diabetes have either DR3/DQ2 or DR4/DQ8 haplotypes,
whereas less than 40 % of normal individuals have these
haplotypes [15].
Many associations with various environmental triggers
have been found in type 1 diabetes, but so far congenital
rubella syndrome and infection with Coxsackie virus have
been more associated with the disease [16]. Another hypoth-
esis is the “hygiene hypothesis” (ie, environmental factors
can also inhibit the development of autoimmunity). Accord-
ing to this theory, environment for young infants is far too
clean, leading to a marked increase in the incidence of “Th1
diseases” such as type 1 diabetes and “Th2 diseases” such as
asthma [17].
There is a large repertoire of cells and cytokines involved
in the autoimmune process in type 1 diabetes. Based on
studies in animal models and in humans, it is well recog-
nized that there is an imbalance between effector cells
(related to β cell destruction) and regulatory cells (related
to immune tolerance). Effector cells and cytokines are basi-
cally pathogenic B cells, pathogenic CD4 and CD8 cells,
and activated dendritic cells, inducible nitric oxide synthase,
interleukin-12 etc. Cells and molecules related to immune
tolerance are regulatory B and T cells modulated by
interleukin-10, indoleamine-2,3,dioxygenase, transforming
growth factor-β etc [18].
In the pathophysiology of autoimmune diabetes it is
observed as an invasion of the islets by mononuclear cells
leading to an inflammatory reaction termed insulitis. β cell
death in the course of insulitis is probably caused by direct
contact with activated macrophages and T-cells, and/or ex-
posure to soluble mediators secreted by these cells, includ-
ing cytokines, nitric oxide and oxygen free radicals [19].
However, accumulating evidence indicates that β cells die
by apoptosis in early type 1 diabetes. Apoptosis is an active,
gene directed process and depends on the parallel and/or
sequential up- and down-regulation of hundreds of genes
[20]. The picture emerging from these findings is that β
cells are not passive bystanders of their own destruction.
They respond to cytokine-mediated damage by triggering
several genes involved in defense/repair and endoplasmic
reticulum stress, by decreasing their most differentiated
functions and their capacity for growth and regeneration,
and by inducing expression of diverse cytokines and chemo-
kines depending on activation or blocking of NF-κB and
STAT-1 [21].
Hematopoietic Stem Cell Transplantation for Autoimmune
Diseases
Hematopoietic stem cells are considered adult stem cells
generally characterized by the expression of CD34 and
Thy1 and the lack of expression of CD38, CD33, and
HLA-DR [22]. Hematopoietic stem cells may be obtained
through direct aspiration of bone marrow, a procedure that
requires anesthesia and aspiration of large volumes of bone
marrow. Alternatively, stem cells can be mobilized from
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bone marrow into the peripheral blood after administration
of growth factors, with or without additional chemotherapy,
followed by harvesting through apheresis.
In 1974, Morton et al demonstrated transmission of a
lupus-like syndrome from genetically predisposed mice to
wild-type irradiated animals, through bone marrow trans-
plants [23]. Several years later, a different research group
was able to treat mice with autoimmune encephalomyelitis
using bone marrow from healthy animals [24]. Numerous
other experiments followed, exploring therapeutic applica-
tions for different autoimmune diseases [25, 26]. In the
beginning, only allogeneic bone marrow cells were used
for transplants and the animals, although remitted from the
original autoimmune disease, presented a sometimes equally
or more severe graft-vs-host disease, caused by an immu-
nological aggression from the grafted lymphocytes against
the host tissues. A turn in history happened in 1991, when
Knaan-Shanzer et al were able to induce remission of mouse
models of adjuvant arthritis using autologous bone marrow
grafts [27]. This first and unexpected model of autologous
transplantation for an autoimmune disease surprised the
scientific community and began a new research line. It
was now possible to avoid graft-vs-host disease and inves-
tigate the applications of the much less aggressive autolo-
gous transplantation.
A second push for stem cell transplantation towards the
treatment of autoimmune diseases came from clinical obser-
vations of bone marrow transplantation, procedure that has
been used for decades in the treatment of hematological
disorders. Ablative or suppressive doses of chemo or radio-
therapy are applied to the patient, followed by infusion of
autologous (same donor), syngeneic (identical twin) or al-
logeneic (different donor) hematopoietic stem cells har-
vested from the bone marrow or peripheral blood. The
stem cell infusion aims to repopulate the destroyed bone
marrow, thereby reestablishing the hematopoietic tissue.
Since 1997, sporadic publications have reported cases of
patients bearing concomitant hematological and autoim-
mune diseases, which have presented remission of both
disorders after bone marrow transplantation [28]. In 2004,
Marmont analyzed 38 such cases from the literature and
from his personal experience and demonstrated that both
autologous and allogeneic transplants were effective in the
control of autoimmune manifestations in humans [29]. Sim-
ilarly to the observations in animals, allogeneic transplants
in humans seemed to induce better control of the autoim-
mune diseases over time. A careful analysis, however,
reveals that autologous transplants for hematological dis-
eases do not usually involve any kind of T cell depletion,
and auto reactive lymphocytes are injected with the graft,
thus perpetuating the autoimmune disease. The same publi-
cation has addressed the impact of bone marrow transplan-
tation on type 1 diabetes; 3 patients who had type 1 diabetes
for more than 3 years remained diabetic after transplanta-
tion, without any change in the metabolic profile [29].
Since 1996, hematopoietic stem cell transplants for auto-
immune diseases have been reported [30, 31]. Initial pub-
lications established safety of the procedure, followed by
evaluations of efficacy for different disease subsets. Today,
over 1800 transplants for autoimmune diseases have been
registered all over the world [32]. Most cases are of multiple
sclerosis, followed by systemic sclerosis, systemic lupus
erythematosus and several other diseases less frequently
included. The main concerns are to maintain safety, detect
disease subsets that may benefit most from the procedure,
and improve long-term disease remission.
Different centers use slightly divergent procedures, but in
most cases patients are initially mobilized with G-CSF and
cyclophosphamide, followed by peripheral blood cell har-
vesting through apheresis. Cells may be manipulated for
lymphocyte removal and are cryopreserved in dimethyl
sulfoxide (DMSO). In a second phase, patients receive
immunosuppressive or even myeloablative doses of chemo
or radiotherapy associated to anti-thymocyte (ATG) or anti-
lymphocyte globulin (ALG), followed by intravenous infu-
sion of the previously cryopreserved unmanipulated hema-
topoietic stem cells. The use of ATG/ALG promotes an in
vivo depletion of T-cells and some, but not all transplant
centers, believe that additional graft selection can be
waived. This is a point of controversy, still to be determined
by future comparative studies.
Specific mechanisms of action of hematopoietic stem cell
transplants for autoimmune diseases are still undetermined,
and we do not exactly know if the above mechanisms are a
consequence of high dose immunosuppression, hematopoi-
etic stem cell infusion, or both. In general, the immune
system becomes more tolerant to auto-antigens. Immuno-
logical reconstitution investigations evidence an increase in
naive lymphocytes, recently emigrated from the thymus, an
increase in the population of T-regulatory cells and a nor-
malization of the T-cell receptor repertoire, all indicators of
a renewed immune system. These changes are associated
with disease remission and are reversed with disease reacti-
vation, indicating persistence of the autoimmune clone [33,
34]. De Oliveira and colleagues showed that another effect
of “immunologic reset” is up-regulation of fas and fasL pro-
apoptotic genes expression in patients’ peripheral blood
mononuclear cells after autologous hematopoietic stem cell
transplantation [35].
Although immunological resetting seems to be the main
therapeutic mechanism of these transplants, some other
effects of stem cells are questioned. The potential of the
transplanted hematopoietic cells to directly differentiate into
pancreatic β cells is one issue. In some diseases, repair is
observed or at least suggested after transplantation, but
whether it is promoted by the injected cells or through
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paracrine effects upon the tissue resident cells has not yet
been determined [36]. Another point of discussion concerns
the use of autologous or allogeneic grafts. Autologous trans-
plants are safer, but may implicate in higher rates of disease
reactivation. Allogeneic transplants, on the other hand, bear
the risk of graft-vs-host disease, but may induce longer
remission, not only because of avoiding the infusion of auto
reactive lymphocytes within the graft, but also because
circulating donor lymphocytes may have a long-lasting sur-
veillance function, eliminating possible host auto reactive
lymphocytes that may have survived therapy. This is called
the graft-vs-autoimmunity effect [29].
Most centers consider allogeneic transplants excessively
aggressive for autoimmune diseases, whose mortality rates
are relatively low compared with hematological malignan-
cies [37]. Therefore, some researchers support the use of
autologous transplants associated with maintenance drugs
after transplantation or intensifying the conditioning regi-
men by addition of immunosuppressive or immunomodula-
tory agents [38].
Clinical Trials Analyzing the Effects of Nonmyeloablative
Immunosuppression Followed by Autologous
Hematopoietic Stem Cell Transplantation in Type 1
Diabetes
Based on the theory of possible reconstitution of immune
tolerance after “immunologic reset”with autologous nonmye-
loablative hematopoietic stem cell transplantation, the optimal
time to apply this therapy is soon after the clinical diagnosis
(Fig. 1) [39, 40]. As discussed above, the higher the residualβ
cell mass, the lower the incidence of chronic complications in
type 1 diabetes. This approach is somewhat different from
research protocols for other disabling autoimmune diseases
such as systemic lupus erythematous, multiple sclerosis, and
scleroderma that use stem cells transplantation only in cases of
failure of traditional immunologic treatments. Patients with
long-term type 1 diabetes are less likely to achieve therapeutic
success with autologous hematopoietic stem cells transplanta-
tion because they havemuch less functioningβ cells and there
is no evidence that hematopoietic stem cells are able to directly
differentiate into β cells [36].
In the face of all discussed above, our research group of
the Faculty of Medicine of Ribeirão Preto in Brazil started in
2003 a pioneer phase I/II study of autologous nonmyeloa-
blative hematopoietic stem cell transplantation in patients
with newly diagnosed type 1 diabetes [41••, 42••]. Patients
were mobilized with 2 g/m2 cyclophosphamide plus a
granulocyte-colony stimulating factor. Stem cells were then
harvested from the peripheral blood through apheresis and
cryopreserved in 10 % DMSO, unselected. After approxi-
mately 15 days from beginning of mobilization, patients
were conditioned with 200 mg/kg cyclophosphamide plus
4.5 mg/kg rabbit anti-thymocyte globulin, followed by in-
travenous infusion of previously collected unmanipulated
autologous hematopoietic stem cells. A subsequent neutro-
penic phase lasted about 6 days, during which fever and
infections were closely monitored and treated preemptively
with broad spectrum antibiotics. After leukocyte engraft-
ment, patients were discharged from the hospital and trans-
ferred to an outpatient clinic, with regular monitoring of
glycemic status, hematological recovery and infections.
Since 2008, every patient who resumed insulin use started
to use sitagliptin 100 mg/day.
A similar protocol was conducted at the University of
Nanjing in China and was published in 2012 [43•]. The
group of the University of Warsaw in Poland published an
almost similar study in 2009. In the latter protocol, they
included 2 or 3 plasmaphereses before the mobilization
regimen with the theoretic objective to remove circulating
antibodies and immunological complexes. As part of the
endocrine control, all patients used acarbose after transplan-
tation to help control glucose levels (up to 300 mg/day)
Fig. 1 Temporal evolution of β
cell mass in type 1 diabetes
mellitus; the dark area
represents the optimal time
when autologous hematopoietic
stem cell transplantation is most
appropriate to preserve residual
β cell mass
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[44•, 45]. Some laboratory and demographic characteristics
of patients included in the 3protocols are shown in Table 1.
In theory, factors associated to better β cell preservation
are conditions known to be accompanied by larger β cell
mass and higher probability of disease remission: older age
at diagnosis, absence of previous diabetic ketoacidosis,
shorter time of disease, higher C-peptide levels at diagnosis,
and lower markers of autoimmunity [18]. However, since
most trials included only a small number of patients, statis-
tical significance was not achieved with many of these
variables.
In these non-randomized, uncontrolled trials, 22 % to
84 % of the patients presented periods free from insulin
varying from months to years and all these studies presented
temporal increments in C-peptide levels compared with
pretreatment values after 3 or 4 years. The smallest propor-
tion of patients insulin-free occurred in the Chinese protocol
and it maybe due to the fact that they enrolled more patients
with diabetic ketoacidosis and with longer time of clinical
diagnosis.
In the Chinese trial, the survival of remaining β cells was
positively associated with the preexisting C-peptide levels but
negatively with preexisting autoantibodies. The numbers of
infused CD34+ cells were positively correlated with the con-
centrations of serum interleukin-10, interleukin-4, transform-
ing growth factor-β and fasting C-peptide but negatively
correlated with the levels of serum tumor necrosis factors -α
and insulin doses after stem cell transplantation.
Some criticism has come because of the fact that these
trials were not designed with a control group. However, it is
almost impossible to include a consecutive number of
patients who coincidently became insulin-free for months
or years simply because of a honeymoon phase.
In the Brazilian trial, the vast majority of patients who
resumed insulin needed only one injection of long-acting
insulin per day at low doses; SF-36 score of quality of life
improved significantly among enrolled patients in a
medium-term period (data not published).
Recent trials using less severe immunointerventions such
as teplizumab [46], daclizumab [47], etanercept [48], abata-
cept [49], and rapamycin + interleukin-2 [50] have failed in
promoting insulin independence and in making an increase
in C-peptide levels in a short follow-up. The possible ex-
planation is that these drugs act only in limited steps of the
autoimmune process of the disease. At the present time,
“immunologic reset” provided by autologous nonmyeloa-
blative hematopoietic stem cell transplantation remains the
only treatment capable of reversing type 1 diabetes in
humans.
In one hand, if the benefits of autologous hematopoietic
stem cell transplantation are closely related to the wide
immunosuppression, risks are also related to this procedure.
We must take into account that newly diagnosed diabetic
patients differ from patients with hematological malignan-
cies, who have classic indications for this approach. From
this point of view it is expected that immunoablation can be
a safer procedure in this group of individuals. The vast
majority of enrolled patients presented only mildly acute
side effects such as chemotherapy-related fever, nausea,
vomiting, headache, alopecia, urticaria, rash, and diarrhea.
The only severe infectious complication was bilateral pneu-
monia that occurred in 2 Brazilian patients and was rapidly
cured.
Concerns also exist about late complications. A large
retrospective survey of fertility after stem cell transplanta-
tion involving 37,362 patients revealed that only 0.6 % of
Table 1 Laboratory and demographic characteristics of patients included in clinical trials of hematopoietic stem cell transplantation in type 1
diabetes
Brazilian trial28 Polish trial 29 Chinese trial 31
Number of patients 23 8 13
Age at diagnosis, y (mean, range) 18.4 (13–31) 25.8 (19–32) 14.1 (8.3–20.8)
Mean number of unmanipulated infused CD34+ cells 10.5×106 /kg 4.1×106 /kg 4×106 /kg
Diabetes duration at enrollment, months (mean, range) 1.2 (0.8–1.8) 2 (1.8–2.4) 5 (2.2–10.6)
HbA1c at diagnosis, % (mean, range) 8.4 (5.4–11.6) 12.3 (8.4–16.7) 9.1 (5.3–15.5)
n (%) with DKA 3 (13) 0 10 (77)
Daily insulin dose before treatment, IU/Kg (mean, range) 0.41 (0.13–0.59) 0.39 (0.1–0.64) Not available
Mean fasting C-peptide, ng/mL 1.02 (0–1.28) 0.71 (0.3–2.2) 0.69 (0.48–1.99)
Follow-up, months (mean, range) 29.8 (7–58) 7 (3–16) 42.3 (31–54)
Patients continuously free from insulin, n (%) 12 (52) 7 (87.5) 2 (15.2)
Mean period patients became continuously free from insulin, mo (range) 31 (14–52) 6 (2–15) 42 (36–48)
Patients transiently free from insulin, n (%) 8 (34.7) 1 (12.5) 1 (7.6)
Mean period patients became transiently free from insulin, mo (range) 17.7 (6–47) Not available 7
DKA diabetic ketoacidosis.
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patients conceived after autologous or allogeneic stem cell
transplantation [51]. Several studies have demonstrated that
a younger age (<25 years) at transplantation is an important
predictor of gonadal function recovery [52–54]. However, it
is important to point out that there is no long-term analysis
exclusively in patients with benign diseases undergoing
autologous hematopoietic stem cell transplantation.
Interestingly, in the Brazilian trial, none of the 13 ana-
lyzed males had normozoospermia before or after transplan-
tation. A total of 4 patients had low seminal volume, 2
patients had low sperm count, 13 patients had low sperm
motility, and 11 patients had morphological abnormalities.
After treatment, mean sperm concentration and motility
were low, and sperm concentration decreased significantly
compared with pretreatment values. Two patients had low
seminal volume and all of them had low sperm counts and
low sperm motility. In patients with normally formed sperm,
the count was initially low and decreased significantly after
treatment. In addition, after treatment, the incidence of se-
vere sperm damage (oligoasthenoteratozoospermia) in-
creased from 15.4 % to 50 % of patients in comparison
with pre-treatment sperm evaluation. Of note, one of the
patients who declined to collect a semen sample 2 years
after treatment had fathered a child 6 months earlier and
another patient who provided a semen sample at 2 years
fathered a child 3 years after the collection [55•]. Two
patients fathered children 2 years after transplantation. Other
patients are not interested in having children so far.
During long-term follow-up, there was 1 case each of
Graves’ disease, transient hyper gonadotropic hypogonad-
ism, and autoimmune hypothyroidism, and these complica-
tions were not related to the status of insulin use. These late
endocrine dysfunctions may be caused by autoimmune dys-
regulation associated with the transplant procedure per se
[56], or by autoimmune polyendocrine syndrome frequently
associated with type 1 diabetes [57].
Conclusions
Autologous hematopoietic stem cell transplantation seems
to be effective in limited group of recent-diagnosed type 1
diabetic patients. In spite of the adverse effects, this proce-
dure was able to increase C-peptide levels along with great
reductions or even suspension of insulin use in the majority
of patients.
The cohort of type 1 diabetic patients treated with autol-
ogous hematopoietic stem cell transplantation is still being
followed for occurrence of long-term complications. Mech-
anistic analysis is being conducted to explore the immuno-
logic effects of high dose immunosuppression and the
causes of relapse presented by some patients. In our opinion,
it is possible that even high dose immunosuppression with
cyclophosphamide plus ATG is not able to completely de-
plete peripheral auto-reactive T lymphocytes.
To the best of our knowledge, high dose immunosuppres-
sion followed by hematopoietic stem cell transplantation is
the only immunotherapy capable of restoring glucose ho-
meostasis in type 1 diabetic patients. A multicenter con-
trolled randomized phase I/II trial has been underway
since 2011 to address some of the unsolved questions and
concerns regarding the risks and possible benefits of the
procedure [58]. It is expected that this ongoing research
protocol definitely figures out why some patients have re-
sumed insulin use and whether the period free from insulin
is merely a honeymoon phase. Moreover, other research
groups are also individually enrolling patients for similar
protocols.
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